TY  - JOUR
AU  - Sperber, Pia Sophie
AU  - Hotter, Benjamin
AU  - Endres, Matthias
AU  - Prüss, Harald
AU  - Meisel, Andreas
TI  - Anti-NMDA-Receptor GluN1 Antibody Serostatus Is Robust in Acute Severe Stroke.
JO  - Diagnostics
VL  - 15
IS  - 24
SN  - 2075-4418
CY  - Basel
PB  - MDPI
M1  - DZNE-2025-01508
SP  - 3132
PY  - 2025
AB  - Background: Anti-N-methyl-D-aspartate IgM and IgA antibodies (NMDAR1-abs) are associated with unfavorable stroke outcomes and may be risk factors thereof. However, to utilize NMDAR1-abs serostatus for risk assessment in acute stroke, it is crucial to understand the robustness of serostatus during this phase. Therefore, we investigated the robustness of NMDAR1-abs serostatus and titer levels up to seven days after stroke. Methods: In this exploratory analysis of the multicenter STRAWINSKI trial (identifier: NCT01264549), patients with severe ischemic stroke (NIHSS ≥ 9) in the middle cerebral artery territory were included. The first blood sample was taken within 36 h and then daily from day two to seven after stroke. NMDAR1-abs immunoglobulin (Ig)A and IgM were assessed in serum using cell-based assays. We initially measured NMDAR1-abs in the total cohort on day 1. Subsequently, in samples from seropositive and matched seronegative patients, we measured NMDAR1-abs on each following day. Titer dilutions started from 1:10 up to 1:1000. Seropositivity was defined as any titer > 0. Results: Out of 171 patients (mean age = 76 [SD = 11], median NIHSS = 15 [IQR = 12-18]), 16 (9
KW  - NMDA-receptor (Other)
KW  - antibodies (Other)
KW  - biomarker (Other)
KW  - stroke (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41464133
DO  - DOI:10.3390/diagnostics15243132
UR  - https://pub.dzne.de/record/283101
ER  -